During the corresponding time, Biocryst Pharmaceuticals Inc recorded a revenue increase by 33.61 % year on year, sequentially revenue grew by 39.53 %. While revenue at the Biocryst Pharmaceuticals Inc 's corporate clients
RESEARCH TRIANGLE PARK, N.C. BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is making significant strides in treating hereditary angioedema (HAE), a debilitating genetic disorder characterized by recurrent episodes of severe swelling. As of November 18, 2024, the company has announced the Health Services Executive (HSE) in Ireland s endorsement of ORLADEYO (berotralstat) for routine prevention of recurrent attacks in eligible patients aged 12 years and older. This pivotal recommendation marks a transformative moment for HAE patients in Ireland, granting them access to the first oral, once-daily therapy specifically designed to mitigate the frequency and severity of these life-altering episodes.Hereditary an...
Long-Term Prophylactic Benefits of Berotralstat in Hereditary Angioedema: A Promising Future At the American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting, BioCryst Pharmaceuticals is set to present compelling real-world evidence on the efficacy of ORLADEYO (berotralstat) for patients with hereditary angioedema (HAE). This meticulously gathered data sheds light on several promising aspects of berotralstat as a long-term prophylactic treatment for HAE, marking a significant advancement in the management of this complex condition. High Adherence and Persistence: The data presented will highlight the high adherence and persistence rates among patients taking ORLADEYO. Adherence is par...
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) TreatmentRESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 - In a groundbreaking announcement, BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) revealed new analyses of real-world usage of ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE). These analyses highlight the remarkable reduction in attack rates experienced by patients who embarked on ORLADEYO therapy, regardless of the severity of their disease, history of prior prophylaxis, or their C1-inhibitor (C1-INH) level and function. The encouraging findings uncover a potential breakthro...
BioCryst Pharmaceuticals Receives Regulatory Approval for ORLADEYO in Argentina BioCryst Pharmaceuticals, a leading biotechnology company, has recently announced the approval of their drug, ORLADEYO (berotralstat), by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina. This regulatory milestone allows the company to market the oral medication as a prophylactic treatment for hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and above. HAE is a rare genetic disorder characterized by recurring episodes of severe swelling in various body parts, such as the hands, feet, face, or airways. These episodes can be extremely painful and potentially l...
Sources:
Biocryst Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biocryst Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biocryst Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
141.54 %